tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Indutrade Expands Medtech Portfolio with Optimed Acquisition

Story Highlights
Indutrade Expands Medtech Portfolio with Optimed Acquisition

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Indutrade AB ( (SE:INDT) ) has provided an update.

Indutrade AB has acquired the Polish company Optimed Pro-Office, a technical trading company specializing in medical disposables and equipment for hospitals and care providers. This acquisition, which will be integrated into Indutrade’s Life Science business area, is expected to offer growth opportunities and have a marginally positive impact on earnings per share. The acquisition marks Indutrade’s sixth in 2025, enhancing its presence in the medtech sector.

The most recent analyst rating on (SE:INDT) stock is a Hold with a SEK325.00 price target. To see the full list of analyst forecasts on Indutrade AB stock, see the SE:INDT Stock Forecast page.

More about Indutrade AB

Indutrade is an international technology and industrial business group comprising over 200 companies across approximately 30 countries, primarily in Europe. The group focuses on sustainable profitable growth through the development and acquisition of successful companies in selected niches, offering components, systems, and services with significant technical content. Indutrade’s net sales reached SEK 32.5 billion in 2024, and its shares are listed on Nasdaq Stockholm.

Average Trading Volume: 307,001

Technical Sentiment Signal: Hold

Current Market Cap: SEK88.17B

See more data about INDT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1